Rayoqta: Withdrawal of the marketing authorisation application
Table of contents
Overview
Allergan Pharmaceuticals International Limited withdrew its application for a marketing authorisation of Rayoqta for the treatment of age-related macular degeneration.
The company withdrew the application on 17 July 2020.
Key facts
Name |
Rayoqta |
Product number |
EMEA/H/C/005103 |
Active substance |
|
Date of withdrawal |
17/07/2020 |
Company making the application | |
Withdrawal type |
Initial authorisation |
All documents
-
List item
Withdrawal assessment report for Rayoqta (PDF/2.63 MB)
Adopted
First published: 21/10/2020
EMA/CHMP/279665/2020 -
List item
Withdrawal letter: Rayoqta (PDF/38.35 KB)
First published: 24/07/2020 -
List item
Questions and answers on the withdrawal of application for the marketing authorisation of Rayoqta (abicipar pegol) (PDF/136.12 KB)
First published: 24/07/2020
EMA/389021/2020 -
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').